Amyl Therapeutics: Funding, Investors & Team (Sep 2026)
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
Amyl Therapeutics has raised $6.5M across 1 funding round on record, the most recent an undisclosed round of $6.5M announced in Nov 2023.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Amyl Therapeutics Company Profile and Key Stats
Latest funding round on record: Nov 2023.
Amyl Therapeutics Funding Rounds
Amyl Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Amyl Therapeutics Funding Compared to Other Biotechnology Startups
Amyl Therapeutics' latest round of $6.5M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Amyl Therapeutics in Biotechnology and Liège
Companies Similar to Amyl Therapeutics
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Nyxoah is a health-technology company focused on the development and commercialization of innovative…
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
Amyl Therapeutics Funding FAQs
What does Amyl Therapeutics do?
Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis. Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.
How much funding has Amyl Therapeutics raised?
Amyl Therapeutics has raised $6.5M across 1 round on record. The most recent is an undisclosed round of $6.5M announced in Nov 2023.
When did Amyl Therapeutics last raise funding?
Amyl Therapeutics' most recent funding round on record is an undisclosed round of $6.5M, announced in Nov 2023.
Who is the CEO of Amyl Therapeutics?
Pierre Vandepapeliere is listed as CEO at Amyl Therapeutics.
Where is Amyl Therapeutics headquartered?
Amyl Therapeutics is based in Liège, Liege, Belgium.
How many employees does Amyl Therapeutics have?
Amyl Therapeutics is in the 1-10 employee band.
How does Amyl Therapeutics' funding compare to other Biotechnology startups?
Amyl Therapeutics' latest round of $6.5M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Amyl Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Amyl Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.